NovoCure (NVCR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.09
- Estimate
- -$0.23
- Surprise
- +61.7%
- Revenue (period 2026-09-30)
- $193.4M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
NovoCure (NVCR) reported a narrower loss than forecast — adjusted EPS of -$0.09 against the -$0.23 estimate (a 61.7% beat on a still-unprofitable quarter).
Coverage in the report window
- Evercore ISI Group Maintains Outperform Rating on Novocure, Lowers Price Target — fiscal.ai, 2026-10-31
- Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15 — benzinga, 2026-10-30
- Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20 — benzinga, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVCR Sell at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +61.7% surprise compares with a +37.0% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Concentration risk — Product: Optune Gio (glioblastoma)
- Quality below floor (3.8 < 4.0)
- Momentum score 1.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.76
- Price target
- $22.74
- Stop
- $10.37
- Upside to target
- +111.3%
- Reward-to-risk
- 7.9:1
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
NVCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.30B
- P/E (fwd)
- -15.3
- 52-week range
- $9.82–$21.45
- Off 52-week high
- 49.8%
- RSI (14)
- 30
- Volume vs avg
- 0.32×
- Score today
- 5.5/10